A novel angiogenic microRNA drug might be a new option for the treatment of ischemic cardiovascular disease, according to a new study (“Nuclear microRNA-466c regulates Vegfa expression in response to ...
BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for ...